Table3_A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1).docx

Background<p>The approval of eslicarbazepine acetate (ESL) by the Food and Drug Administration (FDA) in 2013 marked an advancement in the treatment of adult patients with partial-onset seizures. However, there still remains a paucity of real-world studies regarding the adverse events (AEs) ass...

Full description

Saved in:

Bibliographic Details
Main Author:	Huafei Tang (19710232) (author)
Other Authors:	Jing Xu (15337) (author), Xian Zhang (191440) (author), Chunliang Chen (5587097) (author), Ge Song (1754242) (author), Rui Ma (239028) (author), Jinjing Zhao (15070693) (author), Qiang Zhao (105948) (author)
Published:	2024
Subjects:	Pharmacology Basic Pharmacology Clinical Pharmacology and Therapeutics Clinical Pharmacy and Pharmacy Practice Pharmaceutical Sciences Pharmacogenomics Toxicology (incl. Clinical Toxicology) Pharmacology and Pharmaceutical Sciences not elsewhere classified eslicarbazepine acetate ESL FDA pharmacovigilance analysis AES
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Table3_A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1).docx

Similar Items